Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Short Interest Up 102.3% in June

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 44,712 shares, a growth of 102.3% from the June 15th total of 22,107 shares. Based on an average daily trading volume, of 25,828 shares, the short-interest ratio is presently 1.7 days. Currently, 0.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $4.00.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Rangeley Capital LLC lifted its holdings in Barinthus Biotherapeutics by 88.8% in the 1st quarter. Rangeley Capital LLC now owns 159,465 shares of the company’s stock valued at $91,000 after purchasing an additional 75,024 shares in the last quarter. Renaissance Technologies LLC boosted its position in Barinthus Biotherapeutics by 115.8% during the fourth quarter. Renaissance Technologies LLC now owns 143,100 shares of the company’s stock worth $100,000 after acquiring an additional 76,800 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its position in Barinthus Biotherapeutics by 108.2% during the second quarter. Baird Financial Group Inc. now owns 192,461 shares of the company’s stock worth $179,000 after acquiring an additional 100,000 shares during the last quarter. 25.20% of the stock is owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Stock Up 2.3%

Shares of BRNS stock traded up $0.01 during trading hours on Wednesday, hitting $0.63. 1,898 shares of the company’s stock were exchanged, compared to its average volume of 56,341. Barinthus Biotherapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.92. The firm has a market cap of $25.57 million, a P/E ratio of -0.49 and a beta of -0.41. The firm has a 50 day moving average of $0.67 and a two-hundred day moving average of $0.66.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.14.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.